**Core Concept**
The Blood Safety Programme is a crucial initiative to ensure the quality and safety of blood and blood products. It involves various tests to detect infectious diseases and other contaminants. The programme aims to protect recipients of blood and blood products from transfusion-transmitted infections.

**Why the Correct Answer is Right**
The Blood Safety Programme includes a range of tests, including serological tests for infectious diseases such as HIV, Hepatitis B and C, Syphilis, and Malaria. These tests are essential to detect antibodies or antigens that may indicate an infection. For instance, the HIV test detects the presence of antibodies against the virus, while the Hepatitis B test detects the presence of surface antigen (HBsAg). These tests are critical to prevent the transmission of infectious diseases through blood transfusions.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because serological tests for infectious diseases are indeed part of the Blood Safety Programme.

**Option B:** This option is incorrect because molecular tests, such as PCR (Polymerase Chain Reaction), may be used to detect specific genetic material of infectious agents, but serological tests are the primary method used in the Blood Safety Programme.

**Option C:** This option is incorrect because HLA (Human Leukocyte Antigen) typing is not a compulsory test under the Blood Safety Programme.

**Option D:** This option is incorrect because CMV (Cytomegalovirus) screening is not a compulsory test under the Blood Safety Programme.

**Clinical Pearl / High-Yield Fact**
It's essential to note that the Blood Safety Programme is not limited to serological tests alone. Other tests, such as viral inactivation and pathogen reduction methods, may also be used to ensure the safety of blood and blood products.

**Correct Answer: D. CMV screening is not a compulsory test under the Blood Safety Programme.